Pressure BioSciences (OTCQB: PBIO), a leader in the
development and sale of broadly enabling, pressure-based instruments,
consumables, and platform technology solutions to the life sciences and other
industries, today announced that in 2019 – for the second straight year – over
20 scientific papers highlighting the advantages of PBI’s patented pressure
cycling technology (“PCT”) platform were published worldwide. The publications,
authored by independent scientists from academia, government, and industry,
highlighted the powerful and enabling benefits of the PCT Platform in such
critical areas as cancer research, food safety, and proteomics. “PCT-related
scientific papers published in 2019 highlighted new and/or improved
applications of the PCT Platform in a number of important and exciting areas of
research, including cancer, food safety, and proteomics,” PBI’s Global Director
of Sales and Marketing Roxana McCloskey said in the news release. “We are
particularly pleased that several publications described protocols for
combining the PCT Platform with existing technologies from other companies to
fill a significant unmet need for high throughput protein processing of cancer
biopsy tissues.”
To view the full press release, visit http://ibn.fm/Gpxin
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. The company’s products are based on
the unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions (e.g., cell lysis, biomolecule extraction).
PBIO’s primary focus is in the development of PCT-based products for biomarker
and target discovery, drug design and development, biotherapeutics
characterization and quality control, soil & plant biology, forensics, and
counter-bioterror applications. Additionally, major new market opportunities
have emerged in the use of its pressure-based technologies in the following
areas: (1) the use of its recently acquired, patented technology from BaroFold,
Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract
services sector, and (2) the use of its recently-patented, scalable, high-efficiency,
pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable
nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii)
prepare higher quality, homogenized, extended shelf-life or room temperature
stable low-acid liquid foods that cannot be effectively preserved using
existing non-thermal technologies. For more information, visit the company’s
website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.htm
